Bringing Attention to Renal Cell Carcinoma (RCC) on World Kidney Day
Novartis Dedication to the RCC Community Around the World
Mar 10, 2016
Renal cell carcinoma (RCC) is a rare type of cancer; however, it comprises about 90% of all kidney cancers. An estimated 338,000 patients around the world are diagnosed with RCC each year, and more than 30% have an advanced stage of the disease. This number does not include the family and friends who are also impacted.
Although advanced RCC is not curable, important developments have been made in recent years, including:
the development of therapies that target specific pathways that allow the tumor to grow
the advent of immunotherapies that help the body’s immune system fight the cancer
The RCC scientific community knows a lot already – including important pathways that drive RCC tumor growth. But there is also a lot we are still trying to understand, including how these pathways interact, what other pathways may play a role in the progression or growth of the tumor and how the immune system can be harnessed to help fight RCC.
Recent treatment advances have led to renewed hope in RCC. They have also led to new questions around how these therapies should be used including: Which patients might benefit the most? What is the appropriate sequence of these drugs? Will combining drugs make a difference? Which ones can be combined for maximum benefit?
These are important questions and we are at the forefront of finding answers and bringing the next generation of treatment to patients, working tirelessly to explore different hypotheses about individual and combination therapies for RCC.
In addition to our commitment to help find solutions for the future, we remain grounded in the present. Our global footprint ensures that we are able to make our current therapies available and accessible to people living with and fighting advanced RCC around the world.
Novartis would like to honor the advanced RCC community, including patients, their caregivers and healthcare teams, as well as researchers and patient advocates and to renew our dedication to transforming care for those living with and managing this disease. For more information, please visit www.AlliesinRCC.com.